---
schema_version: "secwatch.filing_event.v1"
accession: "0001437402-25-000016"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:17:56.771572+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ardelyx Q3 2025: product revenue $105.5M, IBSRELA +92% YoY, guidance raised

## Summary
- Total Q3 product revenue $105.5M (+15% YoY); net loss $1.0M ($0.00 per share).
- IBSRELA revenue $78.2M (+92% YoY, +20% QoQ); 2025 guidance raised to $270-275M.
- XPHOZAH revenue $27.4M (+9% QoQ); YoY decline due to loss of Part D coverage.
- Cash $242.7M; new NHE3 inhibitor RDX10531 with IND submission targeted for 2026.
- Appointed Sue Hohenleitner as CFO effective Nov 4, plus new CMO and CTO in Q3.

## SEC filing metadata
- accession: 0001437402-25-000016
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000143740225000016/0001437402-25-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000143740225000016/ardx-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437402-25-000016
- JSON: https://secwatch.observer/filing/0001437402-25-000016.json
- Plain text: https://secwatch.observer/filing/0001437402-25-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.